Drug Type Small molecule drug |
Synonyms (1R,2R)-1,2-cyclohexane-diaminepyrophosphato-platinum(II), Imifoplatin, Phosphaplatin PT-112 |
Target |
Mechanism DNA inhibitors(DNA inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationSpecial Review Project (CN), Orphan Drug (US) |
Molecular FormulaC6H14N2Na2O7P2Pt |
InChIKeyJTEYQLFSZYNTNY-DDCZJXQTSA-J |
CAS Registry1109292-06-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Thymic Epithelial Tumor | Phase 2 | US | 06 Apr 2022 | |
Hepatocellular Carcinoma | Phase 2 | CN | 07 Mar 2018 | |
Hepatocellular Carcinoma | Phase 2 | CN | 07 Mar 2018 | |
Hepatocellular Carcinoma | Phase 2 | CN | 07 Mar 2018 | |
Advanced Malignant Solid Neoplasm | Phase 2 | US | 01 Jul 2014 | |
Advanced Malignant Solid Neoplasm | Phase 2 | FR | 01 Jul 2014 | |
Metastatic castration-resistant prostate cancer | Phase 2 | US | 01 Jul 2014 | |
Metastatic castration-resistant prostate cancer | Phase 2 | FR | 01 Jul 2014 | |
Multiple Myeloma | Preclinical | - | 07 Feb 2018 | |
Non-Small Cell Lung Cancer | Preclinical | TW | 01 Aug 2016 |
Phase 2 | 11 | (dwhvqyvlkl) = oroxqfnobu zifkfmqzsg (efivivrnov ) View more | Positive | 05 Oct 2023 | |||
NCT05104736 (ASCO2023) Manual | Phase 2 | 10 | (jisnhyzwdx) = njytryadqf kmilksjssy (nmlgomjxzm ) View more | Positive | 26 May 2023 | ||
Phase 2 | 18 | (arvihbyyng) = Common treatment-related adverse events (TRAEs) were anemia (50%), fatigue (50%), thrombocytopenia (44%), nausea (44%) and anorexia (44%). nxcjaspqds (wmqxnoskro ) | Positive | 08 Dec 2022 | |||
NCT02266745 (Pubmed) Manual | Phase 2 | Advanced Malignant Solid Neoplasm Last line | 66 | (zruqxwrxlk) = javvzlbayk ghhugqbnat (glznluojnu ) View more | Positive | 27 May 2022 | |
Phase 1 | 36 | (vmjhschgre) = 28% prysvyzswb (vhueyvipln ) View more | Positive | 18 Sep 2020 | |||
Phase 1/2 | 68 | (omhhiqecfj) = The most common PT-112 TRAEs were fatigue (40%, Gr ≤2) with mono-Tx; fatigue (39%, Gr ≤2) with PAVE. cdpnmmgqpy (hteknvoxye ) View more | Positive | 19 Feb 2020 | |||
Phase 1 | 62 | bauyvyuaku(zqarxvpdzv) = no significant acute neurotoxicity was reported in 533 infusions rtaevmomql (tkmaunxopo ) View more | Positive | 22 Oct 2018 |